3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow darapladib: new trials by email Literature Review of darapladib trials Research Report on darapladib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans darapladib, placebo - Endothelial Dysfunction | Phase 3 | Completed | Mayo Clinic | 70 | 2010-02-04 | 2017-04-18 |
| The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial Darapladib 160 mg, Placebo, Standard Therapy - Acute Coronary Syndrome | Phase 3 | Completed | GlaxoSmithKline | 13026 | 2009-12-01 | 2017-08-10 |
| The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial Darapladib, Placebo - Atherosclerosis | Phase 3 | Completed | GlaxoSmithKline | 15828 | 2008-12-01 | 2017-08-10 |
Atherosclerosis (2) · Cardiovascular Diseases (2) · Coronary Disease (2) · Heart Diseases (2) · Acute Coronary Syndrome (1) · Coronary Vasospasm (1)
GlaxoSmithKline (2) · Mayo Clinic (1)
United States (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Bulgaria (2) · Canada (2) · Chile (2) · China (2) · Czechia (2) · Denmark (2) · France (2) · Germany (2) · Hungary (2) · India (2)
Amir Lerman, MD (1)
PMID 21982651, PMID 22496275, PMID 24678955, PMID 24721691, PMID 25173516, PMID 26672609, PMID 26920728, PMID 27329448, PMID 27811204, PMID 28077384, PMID 28735759, PMID 28797349, PMID 28862971, PMID 28912210, PMID 28960596, PMID 29018021, PMID 29066452, PMID 29306475, PMID 30371283, PMID 30897999, PMID 32375553, PMID 32480059, PMID 33439866, PMID 34562103, PMID 35060389, PMID 35861814, PMID 39390990
R01AG031750 (1), R01HL092954 (1)